Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from PYC Therapeutics Limited ( (AU:PYC) ) is now available.
PYC Therapeutics has reported that the Safety Review Committee overseeing its Phase 1 Single Ascending Dose trial of PYC-001 in Autosomal Dominant Optic Atrophy has reviewed four-week safety and tolerability data at the 60 microgram dose. The committee has cleared this dose to move into a Multiple Ascending Dose study, marking a key step forward in clinical development for this first-in-class therapy.
The company will now evaluate repeat dosing of 60 micrograms of PYC-001, alongside existing 10 and 30 microgram cohorts, in an ongoing global Phase 1/2 Multiple Ascending Dose trial in ADOA patients. Outcomes from this study are intended to establish clinical proof-of-concept and support eventual progression to a global registrational trial, with safety and efficacy data expected to be presented through 2026 and 2027.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$5.00 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases with no existing therapies. The ASX-listed biotech currently has three clinical-stage drug development programs, including PYC-001, an investigational therapy targeting the underlying cause of Autosomal Dominant Optic Atrophy, a rare blinding eye disease affecting approximately 1 in 35,000 people worldwide.
Average Trading Volume: 1,468,820
Technical Sentiment Signal: Buy
Current Market Cap: A$1.16B
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.